Valuation: Zai Lab Limited

Market Cap 288.52Cr 251.59Cr 237.56Cr 215.72Cr 404.18Cr 28TCr 405.87Cr 2.85TCr 1.1TCr 14TCr 1.08TCr 1.06TCr 45TCr P/E 2026 *
-11.6x
P/E 2027 * -11.6x
Enterprise Value 242.76Cr 211.69Cr 199.88Cr 181.51Cr 340.07Cr 23TCr 341.49Cr 2.39TCr 923.94Cr 12TCr 911.92Cr 891.68Cr 38TCr EV / Sales 2026 *
5.56x
EV / Sales 2027 * 4.54x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 week+7.77%
Current month+1.83%
1 month+0.91%
3 months+39.62%
6 months+37.04%
Current year+50.00%
1 week 20.6
Extreme 20.6
23.2
1 month 20.4
Extreme 20.4
23.4
3 years 12.6
Extreme 12.6
38.2
5 years 12.6
Extreme 12.6
108
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.89%+7.77%-20.71%-8.26% 288.52Cr
-0.58%+0.43%+31.09%-4.81% 7.84TCr
-2.55%+6.99%+505.27%+47.92% 6.15TCr
-1.11%+5.08%-11.47%-33.91% 5.98TCr
+0.14%-1.20%-11.64%+24.21% 4.65TCr
-0.24%+1.22%+2.26%+151.03% 4.55TCr
-1.62%-0.76%+49.85%-14.92% 3.18TCr
-1.81%+3.16%+45.71%+110.57% 2.54TCr
+0.47%+3.26%-0.77%+142.41% 2.14TCr
+0.27%+1.96%+62.19%+102.81% 1.58TCr
Average -0.78%+2.20%+65.18%+51.70% 4.29TCr
Weighted average by Cap. -0.92%+2.35%+92.67%+39.91%

Financials

2026 *2027 *
Net sales 44Cr 38Cr 36Cr 33Cr 61Cr 4.19TCr 61Cr 430.48Cr 166.12Cr 2.13TCr 163.96Cr 160.32Cr 6.85TCr 55Cr 48Cr 45Cr 41Cr 77Cr 5.3TCr 78Cr 544.56Cr 210.14Cr 2.69TCr 207.41Cr 202.8Cr 8.67TCr
Net income -24Cr -21Cr -20Cr -18Cr -34Cr -2.31TCr -34Cr -237.36Cr -92Cr -1.17TCr -90Cr -88Cr -3.78TCr -21Cr -18Cr -17Cr -16Cr -30Cr -2.03TCr -30Cr -208.18Cr -80Cr -1.03TCr -79Cr -78Cr -3.31TCr
Net Debt -46Cr -40Cr -38Cr -34Cr -64Cr -4.39TCr -64Cr -451.37Cr -174.18Cr -2.23TCr -171.92Cr -168.1Cr -7.18TCr -38Cr -33Cr -31Cr -28Cr -53Cr -3.65TCr -54Cr -375.59Cr -144.94Cr -1.86TCr -143.05Cr -139.88Cr -5.98TCr
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
-
Date Price Change
18/26/18 €22.20 -0.89%
17/26/17 €22.40 +4.67%
16/26/16 €21.40 0.00%
15/26/15 €21.40 +0.94%
14/26/14 €21.20 +2.91%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
25.70USD
Average target price
33.14USD
Spread / Average Target
+28.95%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!